Abstract:1055 Lung cancer is one of the most deadly diseases worldwide and more than 50% of lung cancers contain p53 mutations. Mutant p53 can be classified into two major types, the type I (contact) mutation and type II (conformational) mutation. Important differences between these types have been established, including a higher oncogenic potential for the type II mutation, and the conservation of some wild type activity for type I. We previously established a line of lung specific SPC-p53(273H), a type I p53 mutant, which spontaneously developed lung adenocarcinomas at a median age of 13-15 months. To investigate the role of type II p53 mutant in lung tumorigenesis, a transgenic mouse model with a human mutant p53(175H, Arg to His at codon 175, a type II mutant) was developed. The transgene was placed under the control of the human surfactant protein C (SPC) promoter to selectively express the mutant gene in lung tissue. Transgenic mice were generated by microinjection of a 6.7-kb fragment of the SPC-p53 construct into the pro-nuclei of FVB/N mouse zygotes. Four transgenic founders were identified; 3 females and 1 male. Two female mice did not pass the transgene, whereas the other two passed the transgene to the F1 generation, permitting to establish a line of SPC-p53(175H) transgenic mice. The ratio of transgenic to non-transgenic offspring was 38% (N=157). Expression of the human mutant p53(175H) in lung tissue was evaluated by immunohistochemistry and Western blot analysis using the human specific p53 antibody (DO-7). These analyses showed a high level of human p53 protein in the transgenic lung tissues. The mutant protein was found primarily in the nuclei of pneumocytes from the transgenic mice, and absent in lung tissue from non-transgenic littermates. The male founder developed a lung tumor (12 mm in diameter), identified pathologically as an adenocarcinoma, at necropsy at the age of 12 months. One of the F1 males also developed a lung adenocarcinoma (11mm in diameter) at the age of five months. The remaining mice will be evaluated for the rate of tumor formation at age intervals of 7-9, 10-12 and 13-15 months and compared to the incidence in non-transgenic littermates and type I mutants. The animal models discussed above should provide valuable information on the role of mutant p53 type in lung carcinogenesis and may provide a framework to further evaluate environmental carcinogens and the effects of these mutations on response to treatment interventions.

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

Expression of a Mutant P53 in Lung Specific Transgenic Mice Cause Age-Related Demographic Shift in Lung Tumor Incidence

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Effects of genetic background on tumorigenesis in p53-deficient mice

Alterations Of The P53 Tumor-Suppressor Gene In Transformed Mouse-Liver Cells

BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo

Expression of a P53 Mutant in the Epidermis of Transgenic Mice Accelerates Chemical Carcinogenesis

Transgenic Murine Models of Human Cancer: Bridging the Gap from Mouse to Man

Establishment and Characterization of a Line of Transgenic Mice Harboring a Lung Specific Human Type II P53(175h) Mutation

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

The MMTV/c-myc Transgene and P53 Null Alleles Collaborate to Induce T-cell Lymphomas, but Not Mammary Carcinomas in Transgenic Mice.

Genetic Mechanisms of Tumor Suppression by the Human p53 Gene

Oncogenic and teratogenic effects of p53Y217C, a mouse model of the human hotspot mutant p53Y220C

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

p53 mutant mice that display early ageing-associated phenotypes

Tumorigenesis Of Murine Erythroleukemia Cell Line Transfected With Exogenous P53 Gene

Differential Gain-of-Function Activity of Three P53 Hotspot Mutants in Vivo

Generation and Characterization of P53 Mutant Mice.

Inactivation of p53 tumor suppressor gene acts synergistically with c- neu oncogene in salivary gland tumorigenesis